scPharmaceuticals (SCPH) Competitors $5.64 +0.01 (+0.18%) Closing price 09/23/2025 04:00 PM EasternExtended Trading$5.64 0.00 (-0.09%) As of 09/23/2025 04:14 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock SCPH vs. CVAC, ETNB, DNTH, CALT, ZYME, ELVN, LENZ, COLL, PGEN, and WVEShould you be buying scPharmaceuticals stock or one of its competitors? The main competitors of scPharmaceuticals include CureVac (CVAC), 89BIO (ETNB), Dianthus Therapeutics (DNTH), Calliditas Therapeutics AB (publ) (CALT), Zymeworks (ZYME), Enliven Therapeutics (ELVN), LENZ Therapeutics (LENZ), Collegium Pharmaceutical (COLL), Precigen (PGEN), and WAVE Life Sciences (WVE). These companies are all part of the "pharmaceutical products" industry. scPharmaceuticals vs. Its Competitors CureVac 89BIO Dianthus Therapeutics Calliditas Therapeutics AB (publ) Zymeworks Enliven Therapeutics LENZ Therapeutics Collegium Pharmaceutical Precigen WAVE Life Sciences scPharmaceuticals (NASDAQ:SCPH) and CureVac (NASDAQ:CVAC) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their institutional ownership, earnings, media sentiment, valuation, analyst recommendations, risk, dividends and profitability. Do insiders & institutionals hold more shares of SCPH or CVAC? 89.5% of scPharmaceuticals shares are owned by institutional investors. Comparatively, 17.3% of CureVac shares are owned by institutional investors. 4.8% of scPharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth. Do analysts prefer SCPH or CVAC? scPharmaceuticals currently has a consensus price target of $7.78, suggesting a potential upside of 38.00%. CureVac has a consensus price target of $6.83, suggesting a potential upside of 27.49%. Given scPharmaceuticals' higher possible upside, equities analysts plainly believe scPharmaceuticals is more favorable than CureVac.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score scPharmaceuticals 0 Sell rating(s) 3 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00CureVac 0 Sell rating(s) 4 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.20 Does the media refer more to SCPH or CVAC? In the previous week, CureVac had 2 more articles in the media than scPharmaceuticals. MarketBeat recorded 2 mentions for CureVac and 0 mentions for scPharmaceuticals. CureVac's average media sentiment score of 1.96 beat scPharmaceuticals' score of 0.95 indicating that CureVac is being referred to more favorably in the news media. Company Overall Sentiment scPharmaceuticals Positive CureVac Very Positive Is SCPH or CVAC more profitable? CureVac has a net margin of 38.21% compared to scPharmaceuticals' net margin of -183.55%. CureVac's return on equity of 29.57% beat scPharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets scPharmaceuticals-183.55% -1,647.86% -71.76% CureVac 38.21%29.57%25.41% Which has preferable earnings and valuation, SCPH or CVAC? CureVac has higher revenue and earnings than scPharmaceuticals. scPharmaceuticals is trading at a lower price-to-earnings ratio than CureVac, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioscPharmaceuticals$36.33M8.27-$85.15M-$1.81-3.12CureVac$579.18M2.08$175.50M$0.965.58 Which has more risk and volatility, SCPH or CVAC? scPharmaceuticals has a beta of 0.35, suggesting that its share price is 65% less volatile than the S&P 500. Comparatively, CureVac has a beta of 2.53, suggesting that its share price is 153% more volatile than the S&P 500. SummaryCureVac beats scPharmaceuticals on 12 of the 16 factors compared between the two stocks. Get scPharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for SCPH and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding SCPH and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart SCPH vs. The Competition Export to ExcelMetricscPharmaceuticalsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$300.07M$3.16B$5.76B$10.50BDividend YieldN/A2.36%5.53%4.57%P/E Ratio-3.1221.0476.0426.62Price / Sales8.27252.06469.4291.51Price / CashN/A46.3537.4661.85Price / Book20.899.7813.676.45Net Income-$85.15M-$52.73M$3.29B$271.57M7 Day Performance0.18%3.16%1.83%2.61%1 Month Performance16.29%4.69%3.98%7.28%1 Year Performance18.24%16.37%78.13%29.60% scPharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)SCPHscPharmaceuticals4.3899 of 5 stars$5.64+0.2%$7.78+38.0%+17.3%$300.07M$36.33M-3.1230CVACCureVac4.0825 of 5 stars$5.36+0.4%$6.83+27.5%+73.5%$1.20B$579.18M5.58880News CoveragePositive NewsETNB89BIO2.4711 of 5 stars$8.02-0.6%$28.00+249.1%+92.2%$1.20BN/A-2.2240DNTHDianthus Therapeutics2.7788 of 5 stars$37.04-0.3%$61.57+66.2%+44.7%$1.20B$4.85M-11.4080CALTCalliditas Therapeutics AB (publ)N/A$40.00flatN/AN/A$1.19B$1.60B-21.62180ZYMEZymeworks2.3581 of 5 stars$15.93+1.2%$21.43+34.5%+28.2%$1.18B$122.87M-10.62460Positive NewsELVNEnliven Therapeutics2.5926 of 5 stars$18.50-7.3%$41.20+122.7%-18.6%$1.18BN/A-9.2550Insider TradeLENZLENZ Therapeutics1.4668 of 5 stars$40.01-3.2%$49.60+24.0%+88.2%$1.18BN/A-21.06110Positive NewsCOLLCollegium Pharmaceutical3.8146 of 5 stars$34.92-6.4%$42.33+21.2%-8.7%$1.18B$707.01M33.58210PGENPrecigen4.4087 of 5 stars$3.59-5.3%$8.25+129.8%+284.8%$1.13B$3.92M-8.55190WVEWAVE Life Sciences4.4584 of 5 stars$6.97flat$20.33+191.7%+27.9%$1.11B$108.30M-7.74240 Related Companies and Tools Related Companies CureVac Alternatives 89BIO Alternatives Dianthus Therapeutics Alternatives Calliditas Therapeutics AB (publ) Alternatives Zymeworks Alternatives Enliven Therapeutics Alternatives LENZ Therapeutics Alternatives Collegium Pharmaceutical Alternatives Precigen Alternatives WAVE Life Sciences Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:SCPH) was last updated on 9/24/2025 by MarketBeat.com Staff From Our PartnersWhat The Silver Boom Could Mean For You…AI, electric vehicles, and even global central banks are quietly fueling record demand for silver. This once-o...Goldco Precious Metals | SponsoredWarren Buffett’s #1 AI Stock: Not Mag 7, And NOT on the NasdaqNew Amazon Crisis Could Tank U.S. Stock Market A new panic is halting AI projects at Amazon and could split...Altimetry | SponsoredWhy More Investors Are Using Family Trusts to Protect Their WealthFor many investors, a family trust can be an essential tool for protecting assets, avoiding probate, and ensur...SmartAsset | SponsoredClaim Your Share of $5.39 BILLION in AI Equity ChecksThe U.S. government just took advantage of Public Law 81-774 to crack down on AI companies... In turn, enfo...Angel Publishing | SponsoredIRS Wants Another Check on Sept 15th—What If You Could Keep It Instead?On September 15th, the IRS collects another round of quarterly tax payments—targeting self-employed profession...American Alternative | SponsoredTrump’s new nightmare beginsPorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredIs This Nvidia’s Next Big Invention? (Picture Inside)Nvidia gave investors a chance to make more than 150 times their money with its AI chips known as graphic proc...InvestorPlace | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding scPharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share scPharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
